View More News
BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs
January 29, 2025

BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs
Former CSO of Trilo Therapeutics and Research Fellow atAbbVie joins to lead BioLoomics’ pipeline and combine lysosome targetingantibodies with ADCs
January 29, 2025
Backed by former Google CEO’s VC, a Colorado biotech hatches platform to evolve degraders
January 29, 2025

Backed by former Google CEO’s VC, a Colorado biotech hatches platform to evolve degraders
BioLoomics’ goal is to make a degrader from an antibody in one month
January 29, 2025
BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies
January 29, 2025

BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies
Our mission is to make safer, more effective cancer therapeutics.
January 29, 2025